Paraganglioma of the tongue with SDHB gene mutation in a patient with Graves' disease by Duran Alvarez, Marcela Adriana et al.
726 |    Clin Case Rep. 2019;7:726–730.wileyonlinelibrary.com/journal/ccr3
1 |  INTRODUCTION
Paragangliomas (PGLs) are uncommon neuroendocrine tu-
mors arising from the neural crest‐derived paraganglia of the 
autonomic nervous system, including the adrenal medulla, 
represented by pheochromocytoma (PCC). Most of the sym-
pathetic‐related PGLs are chromaffin and functioning tumors 
associated with epinephrine and/or norepinephrine release. 
Conversely, most of the parasympathetic PGLs are nonchromaf-
fin and nonfunctioning tumors although some of them can pro-
duce dopamine.1,2 Outside the adrenal gland, the most frequent 
location is the head and neck area with a predominance in fe-
male patients. These PGLs are usually parasympathetic tumors 
arising from the carotid body, jugulotympanic paraganglia, and 
the ganglion nodosum of the vagus nerve.1,3,4 Other rarer sites 
of involvement are the thyroid gland, larynx, nose, orbit and 
along the hypoglossal nerve, but occurrence in oral structures 
is extremely uncommon.3,4 To the best of our knowledge, only 
four PGLs of the tongue were reported previously.2,4,5
Most PGLs follow a benign clinical course. Estimated rates 
of malignancy were about 10%; however, long‐term follow‐up 
and advances in genetics confirmed that the real incidence of 
malignancy is higher.6 Currently, there are no reliable histologi-
cal criteria to predict the biological behavior; hence, malignancy 
is defined by the presence of metastases. Bone, lymph nodes, 
lung, and liver are the most frequent metastatic locations.6
These tumors carry the highest degree of heritability 
among human neoplasms. 40% of PGLs harbor a germ-
line mutation and an additional 20%‐30% a somatic muta-
tion.7,8 Up to 14% of apparently sporadic tumors carry occult 
germ-line mutations.7,8 Hereditary syndromes, such as 
multiple endocrine neoplasia (MEN) type 2A and 2B, von 
Hippel‐Lindau (vHL), and neurofibromatosis type 1 (NF‐1) 
are associated with the development of PGLs. In addition, 
hereditary susceptibility also includes five familial PGLs syn-
dromes caused by mutation in the succinate dehydrogenase 
genes (collectively SDHx) that can be screened by immu-
nohistochemistry and identified by sequencing analysis.9,10 
SDHx mutations represent almost 30% of mutated PGLs. 
Other genes associated with individual hereditary PCC/PGL 
syndromes are MAX, TMEM127, KIF1B, EGLN1, and FH, 
with a prevalence of less than 2% for each gene.1
Multinodular goiter, Graves’ disease, and other auto-
immune disorders have been described in patients with 
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Key Clinical Message
We report a case of an apparently sporadic paraganglioma of the tongue with a 
germ-line mutation in a female patient with asymptomatic Graves’ disease. The 
tongue is an unusual primary location. Genetic testing is mandatory in all cases. 
Thyroid gland dysfunction and autoimmune phenomena could be associated with 
some paragangliomas.
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functioning PCC11-17 and nonfunctioning PGLs of the head 
and neck including one case located in the tongue.4
2 |  CASE REPORT
2.1 | Clinical history
A 53‐year‐old female was referred by her physician to the 
Department of Otorhinolaryngology with a swelling in her 
tongue that she noted after she choked on a piece of food. 
Biochemical signs of hyperthyroidism (TSH: 0.005 mU/mL, 
normal ranges: 0.27‐4.20; plasma‐free T4: 2.75 ng/mL, nor-
mal ranges: 0.93‐1.71; plasma‐free T3: 5.36 pg/mL, normal 
ranges: 2.04‐4.40) were detected in a routine analysis three 
months before she choked. Positive antinuclear antibodies 
(ANA: positive in 1/40), antithyroid peroxidase (anti‐TPO: 
127, 8 U/ml, normal ranges: 0.00‐34.00), anti‐TSH receptor 
(2.22 U/L, normal ranges: 0.00‐1.75), and antithyroglobu-
lin (anti‐TGB: 11.98 U/ml, normal ranges: 0.00‐115.00) 
were also detected. Serum calcium was normal (9.95 mg/
F I G U R E  1  Head and Neck CT scan 
showing a nodule in the posterior aspect of 
the tongue (left) with contrast enhancement 
(right)
F I G U R E  2  A, Transoral resection 
of the nodule. B, Panoramic of the tumor 
(H&E × 200). C, Zellballen appearance with 
S‐100 positive sustentacular cells (×200). 
D, Immunohistochemistry for SDHB is 
negative in tumor cells and positive in 
endothelium as an internal control (×400)
(A) (B)
(C) (D)
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dl, normal ranges: 8.6‐10.4).These features are consistent 
with Graves’ disease, although the patient had none of the 
classical symptoms of this disease. Her familial history was 
unremarkable, without antecedents of endocrinal or genetic 
diseases. On physical examination, a nodule bulging under 
the posterior aspect of the tongue was observed. Neither 
dysgeusia nor dysarthria were detected. Head and neck com-
puted tomography (CT) scan evidenced a nodule at the base 
of the tongue with intense enhancement after contrast admin-
istration, suspicious for a hemangioma (Figure 1). No other 
masses were detected on the head and neck area. Thyroid 
gland ultrasound identified two nonspecific millimetric nod-
ules in a normal sized gland. Radioiodine scan showed an 
orthotopic thyroid gland with a diffusely increased uptake. 
After the diagnosis, a thoracoabdominal CT scan ruled out 
adrenal or extra‐adrenal masses. The patient underwent an 
endoscopic transoral resection of the lingual nodule (Figure 
2A). Healing was uneventful.
2.2 | Materials and methods
The surgical specimen was fixed in 10% buffered formalin 
for routine histology and immunohistochemistry. The latter 
was performed using the avidin‐biotin technique. Tested an-
tibodies (all from Dako, Glostrup, DK‐Denmark) included 
chromogranin A, neuron‐specific enolase (NSE), S‐100 pro-
tein, CK AE1/AE3, smooth muscle antigen (SMA), CD‐31, 
carcinoembryonic antigen (CEA), thyroglobulin, calcitonin, 
TTF‐1, HMB‐45, and Ki67. Immunohistochemistry and se-
quencing analysis for SDHx mutations were performed in 
another center using anti SDH B rabbit polyclonal antibody 
(Sigma‐Aldrich Corp). SDHA was also tested on tumor sam-
ple as previously described.9 For molecular analysis, Sanger 
and next‐generation sequencing (NGS) were applied. It was 
used a TruSeq Custom Amplicon 1.5 Kit (Illumina, San 
Diego, CA) to study DNA from tumor and blood samples as 
previously described.10
2.3 | Pathologic findings
The surgical specimen consisted of a rubbery brown nod-
ule, measuring 17 × 15 × 15 mm, with well circumscribed 
borders, partially covered by an intact mucosa. Microscopic 
examination revealed a highly vascularized tumor composed 
of nests of uniform cells with finely granular cytoplasm and 
round nuclei without atypia, mitosis, or necrosis. These cells 
expressed chromogranin A and NSE. A second population 
of S‐100 positive sustentacular cells were detected at the pe-
riphery of the nests with the classical “zellballen” appearance 
described in paraganglioma (Figure 2B,C). The tumor was 
focally transected by surgical margins. Other markers tested 
for differential diagnosis are summarized in Table 1. Ki 67 
showed a very low proliferation rate (<1%). Other potentially 
associated tumor components derived from the neural crest, 
such as ganglioneuroma and melanocytes, were not identi-
fied. Immunohistochemistry for SDHB was negative (Figure 
2D) while SDHA was positive. This result suggested the 
presence of a mutation in any of the SDHx genes but SDHA. 
Mutational analysis confirmed a c.689G>A/p.Arg230His 
mutation in SDHB gene.
3 |  DISCUSSION
3.1 | Primary vs metastatic PGL
The tongue is richly endowed with nerve fibers, and some of 
them are autonomic with minor paraganglia.18 The tongue is 
an unusual primary site for PGLs. Despite the statement that 
metastasis of paraganglioma should be diagnosed only if the 
affected organs lack paraganglia, we consider that any organ 
Marker Result Interpretation
Chromogranin A Positive Favor paraganglioma
NSE Positive Favor paraganglioma
TTF‐1 Negative Exclude thyroid origin, other neuroendo-
crine tumors
Thyroglobulin Negative Exclude thyroid origin
Calcitonin Negative Exclude medullary carcinoma
CEA Negative Exclude medullary carcinoma
CD31 Negative Exclude hemangioma
SMA Negative Exclude glomus tumor
Cytokeratins Negative Exclude carcinoma, other neuroendocrine 
tumors, and thyroid adenoma
S‐100 Positive sustentacular 
cells
Classical paraganglioma
T A B L E  1  Immunohistochemistry in 
differential diagnosis
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can be involved by metastasis; therefore, we ruled out a PGL 
in other primary locations.
3.2 | Catecholamines in diagnosis and 
follow‐up
At least some PGLs of the head and neck produce dopamine.1 
Biochemical diagnosis for this type of PGLs is best achieved 
by measurement of plasma‐free methoxytyramine.1 Some 
adrenal PCC and extra‐adrenal PGLs are nonfunctioning tu-
mors, either primarily or after a metabolic change along the 
pathway of dedifferentiation.1 This fact reveals that normal 
levels of catecholamines or metanephrines should be taken 
with caution. In our case, as the diagnosis of paraganglioma 
was unexpected, catecholamines were investigated after sur-
gery and they were in normal levels. Methoxytyramine test 
was unavailable in our center.
3.3 | Genetics provides relevant biological 
information that histopathology cannot provide
Features such as young age at onset, bilateral and multiple 
tumors suggest an inherited background. Our case is an ex-
ample of an apparently sporadic PGL located in an unusual 
site, and this fact prompted the search for mutations. It was 
identified a germline mutation in SDHB gene that has been 
described in Mediterranean population carrying a 45% of ma-
lignancy risk.19 Germline mutations in SDHx are inherited 
in an autosomal dominant manner with an age‐related pen-
etrance.1,7,8 Genetic testing should be performed in all PGLs.
3.4 | Metabolomics and future directions
More than half of the PGLs susceptibility genes encode en-
zymes involved in the Krebs cycle. SDH is also known as 
the complex II of the oxidative chain. Five subunits (SDHA, 
SDHB, SDHC, SDHD, and SDHAF2) are the components of 
this complex located in the inner mitochondrial membrane. 
SDH catalyzes the oxidation of succinate into fumarate 
within the Krebs cycle. The loss of SDH activity leads to 
a massive accumulation of succinate and high levels of this 
metabolite cause it to act as an oncometabolite, activating the 
hypoxia‐induced signaling pathway related to angiogenesis, 
cell metabolism, and other tumor growth factors.20-22 In ad-
dition, succinate can also promote a particular CpG island 
methylation phenotype (CIMP) by impairment of histone 
demethylation.21 Metabolomics allowed to group PGLs into 
two clusters depending on pathogenesis and catecholamine 
phenotype (Table 2). Cluster 1 PGLs have an “immature” 
biochemical phenotype while cluster 2 PGLs have a “dif-
ferentiated” phenotype.1,7,20,21 This clustering provided new 
strategies for treatment of malignant and metastatic PGLs.22 
The multikinase inhibitor sunitinib has been tested in several 
patients obtaining partial responses in some cases.7,8 At the 
time of this report, the first clinical trial on sunitinib was on-
going (FIRSTMAPPP).
3.5 | Thyroid dysfunction in PGLs
It should be noted that physiologically catecholamines stim-
ulate thyroxin secretion via beta‐adrenergic receptors while 
dopamine inhibits thyroxin release. Symptoms of thyroid hy-
perfunction are quite similar to those of functioning PGLs 
and PCC. Nevertheless, thyroid dysfunction has also been 
reported in some nonfunctioning PGLs.4The common me-
tabolite in the biosynthesis of catecholamines and thyroid 
hormones is the aminoacid tyrosine. A potential link between 
mutated PGL (especially those of the head and neck) and 
thyroid gland dysfunction requires further investigation. As 
many other tumors, PCC/PGL could acquire antigenic prop-
erties capable to elicit an immune response with potential 
cross‐reactivity against normal tissues generating autoim-
mune phenomena, although large series addressing this issue 
are lacking.
3.6 | Patient outcome
Our patient refused a specific follow‐up including genetic 
consultation. After treatment with an antithyroid drug and 
iodine radiation, the patient became hypothyroid and serum 
autoantibodies decreased significantly. The latest thoracoab-
dominal CT scan ruled out the presence of masses or other 
signs of tumor progression. After 18 months from surgery, 
the patient is doing well.
Characteristics Cluster 1 tumors Cluster 2 tumors
Germline or somatic 
mutation
vHL – SDHx – HIF 2a – MDH2.FH 
– PHD2















H&N PGLs, head and neck paragangliomas.
T A B L E  2  Clustering of 
paragangliomas1
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4 |  CONCLUSION
Our case illustrates, to the best of our knowledge, the first 
reported primary PGL of the tongue with a documented mu-
tation in SDHB gene, in a patient with asymptomatic Graves’ 
disease. The tongue is a primary location for PGLs. The 
absence of a familial history or other features suggestive of 
an inherited syndrome should not preclude genetic testing. 
Thyroid gland dysfunction and autoimmunity could be as-
sociated with some nonfunctioning paragangliomas although 
further investigation is needed.
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